ClinicalTrials.gg
Active, not recruitingNCT04685135KRYSTAL-12Updated Aug 11, 2026Results posted

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

A Phase 3 interventional study of MRTX849 and Docetaxel in Metastatic Non Small Cell Lung Cancer and Advanced Non Small Cell Lung Cancer, sponsored by Mirati Therapeutics Inc.. Active, not recruiting at 380 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Mirati Therapeutics Inc. (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
453
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing adagrasib in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 7 under way, 3 of them phase 3. adagrasib · Carcinoma, Non-Small-Cell Lung.

Enrollment
4th of 12
453 · median 77
Started
2021
with 1 other
Phase 3
2 of 12
1 open now
Registered
3rd of 12
by date
Lead sponsor
6 of 12
Mirati Therapeutics Inc.

Among the 12 studies testing adagrasib in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment, is one of 2 that started in 2021, is one of 2 in phase 3, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 12 studies testing adagrasib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adagrasib

adagrasib: first FDA approval 2022 (KRAZATI), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing adagrasib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

03

Conditions studied

  • Metastatic Non Small Cell Lung Cancer
  • Advanced Non Small Cell Lung Cancer

Keywords

  • KRAS G12C
  • Non-small cell lung cancer
  • NSCLC
  • Metastatic Cancer
  • Docetaxel
  • Phase 3 Clinical Trial
  • Adagrasib
  • KRAS
  • KRAZATI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.
  • Candidacy to receive treatment with docetaxel.

Crossover Inclusion Criteria:

  • Evidence of 1.1 defined disease progression on docetaxel per BICR
  • performance status 0-2

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib).
  • Active .

Crossover Exclusion Criteria:

  • Receipt of any other systemic anti-cancer therapy after last administration of docetaxel on the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
453 participants (actual)

Study arms

  • Experimental
    MRTX849

    Drug: MRTX849

  • Active comparator
    Docetaxel

    Drug: Docetaxel

Interventions

  • 21 day cycles

    Also known as: adagrasib, KRAZATI

  • 21 day cycles

    Also known as: Taxotere

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) as Per Blinded Independent Central Review

    Progression-free survival (PFS) is defined as the time from randomization to the date of progression or death due to any cause, whichever occurs first. 95% CI was obtained using Brookmeyer and Crowley method. Participants who are not observed to have progressed or died are censored at the date of last evaluable tumor assessment. Disease progression assessed as per RECISIST 1.1 was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From randomization to the date of progression or death due to any cause, whichever occurs first (up to approximately 143 weeks)

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as the time from randomization to the date of death due to any cause.

    Time frame: From randomization till death due to any cause (up to approximately 143 weeks)

  2. Objective Response Rate (ORR) as Per Blinded Independent Central Review

    Objective Response Rate (ORR) is defined as the percent of participants documented to have a confirmed complete response (CR) or partial response (PR). CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. All target lesions must be assessed. Disease progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm.

    Time frame: From randomization till death or till disease progression or initiation of follow-up anti-cancer therapy or withdrawal of consent prior to minimum efficacy follow-up (up to 143 weeks)

  3. Duration of Response (DOR) as Per Blinded Independent Central Review

    Duration of Response (DOR) in months is defined as the time from date of the first documentation of objective response (CR or PR) to the first documentation of PD or to death due to any cause in the absence of documented PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. All target lesions must be assessed. Disease progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm.

    Time frame: First documentation of objective response (CR or PR) to the first documentation of PD or to death due to any cause (Up to approximately 22 months)

  4. 1-Year Survival Rate

    Time frame: Up to 49 months

  5. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Treatment Emergent Adverse Events (TEAEs) are those that first occur or increase in severity on or after the first dose and not more than 28 days after the last dose, and prior to the initiation of subsequent systemic anti-cancer therapy. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks)

  6. Number of Participants With Maximum CTCAE Grade Laboratory Abnormality in Hematology Parameters

    Blood samples were collected to assess hematology parameters. Adverse events are graded on a scale from 0 to 4 based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0, with Grade 0 being normal Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.

    Time frame: From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks)

  7. Number of Participants With Maximum CTCAE Grade Laboratory Abnormality in Chemistry Parameters

    Blood samples were collected to assess chemistry parameters. Adverse events are graded on a scale from 0 to 4 based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0, with Grade 0 being normal Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.

    Time frame: From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks)

  8. Plasma Concentration of Adagrasib

    Blood samples were collected for assessment of plasma concentration of Adagrasib. Data for participants for which the dose was reduced after receiving starting dose of 600 mg BID, based on physician decision is presented in separate arms.

    Time frame: Day 1 of Cycle 1 (Pre-Dose and Peak), Cycle 2 (Pre-Dose and Peak), Cycle 3 (Pre-Dose), Cycle 5 (Pre-Dose), Cycle 7 (Pre-Dose) (Each cycle is of 21 days)

  9. Change From Baseline in Lung Cancer Symptom Scale (LCSS) Average Total Score

    The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire assesses the following 6 symptoms items (appetite loss, fatigue, cough, dyspnea, hemoptysis, pain) and 3 summary global items (symptom distress, activity level, overall quality of life) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The LCSS average total score is sum of items 1 to 9 divided by the total number of items ((sum of items 1 to 9)/9) ranging from 0 to 100 where high score represent worst outcome. Least Square Mean and Confidence Interval are from a repeated measures model on the response variable change from baseline in LCSS average total score.

    Time frame: Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)

  10. Change From Baseline in Lung Cancer Symptom Scale (LCSS) Average Symptom Burden Index Score

    The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire for average symptom burden index score assesses the following six items (Appetite loss, fatigue, cough, shortness of breath, blood in sputum, pain) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The average symptom burden score is average of all the 6 items ranging from 0 to 100 where high score represent worst outcome. Least square mean and CI are from a repeated measures model on the response variable change from baseline in average symptom burden index score.

    Time frame: Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)

  11. Change From Baseline in Lung Cancer Symptom Scale (LCSS) 3-Item Global Index Score

    The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire for average 3-item global index score assesses the following 3 items (Distress/severity of symptoms from lung cancer, impact on normal activities, quality of life) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The 3 item global index score is average of all the 3 items ranging from 0 to 100 where high score represent worst outcome. LS mean and CI are from a repeated measures model on the response variable change from baseline in 3-item global index score.

    Time frame: Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)

  12. Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Visual Analogue Scale Score

    The Visual Analogue Score (VAS) is a component of the EQ-5D-5L and assesses the patient's self-rated health using a vertical visual analogue scale where numbered 0 (the worst health you can image) to 100 (the best health you can imageine). The smallest change considered clinically meaningful, is defined as a score difference of 7 points.

    Time frame: Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)

  13. Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Health Utility Index Score

    The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. The EQ-5D-5L health utility index (HUI) is assessed using the Crosswalk algorithm for France based on the individual responses to the 5 EQ-5D-5L domains ranging from -0.594 to 1.000. The smallest change considered clinically meaningful, is defined as a score difference of 0.08 points. Least square mean and CI are from a repeated measures model on the response variable change from baseline in health utility index.

    Time frame: Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)

07

Results

Posted Jan 22, 2025

Participant flow

Participant flow — Overall Study
MilestoneAdagrasibDocetaxel
Started301152
Safety population298140
Cross over044
Completed16383
Not completed13869
Withdrew: Death12653
Withdrew: Withdrawal by subject1216

Outcome measures

PrimaryProgression-Free Survival (PFS) as Per Blinded Independent Central Review

Progression-free survival (PFS) is defined as the time from randomization to the date of progression or death due to any cause, whichever occurs first. 95% CI was obtained using Brookmeyer and Crowley method. Participants who are not observed to have progressed or died are censored at the date of last evaluable tumor assessment. Disease progression assessed as per RECISIST 1.1 was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From randomization to the date of progression or death due to any cause, whichever occurs first (up to approximately 143 weeks)
Reported as:
Median · months
Progression-Free Survival (PFS) as Per Blinded Independent Central Review
monthsAdagrasibDocetaxel
Progression-Free Survival (PFS) as Per Blinded Independent Central Review5.49 (4.53 to 6.67)3.84 (2.73 to 4.73)
Statistical analysis
  • Adagrasib vs Docetaxel · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.58 · 95% CI 0.45 to 0.76HR and CI are from stratified Cox proportional hazard model
SecondaryOverall Survival (OS)

Overall survival is defined as the time from randomization to the date of death due to any cause.

Time frame:
From randomization till death due to any cause (up to approximately 143 weeks)

Results for this outcome have not been posted.

SecondaryObjective Response Rate (ORR) as Per Blinded Independent Central Review

Objective Response Rate (ORR) is defined as the percent of participants documented to have a confirmed complete response (CR) or partial response (PR). CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. All target lesions must be assessed. Disease progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm.

Time frame:
From randomization till death or till disease progression or initiation of follow-up anti-cancer therapy or withdrawal of consent prior to minimum efficacy follow-up (up to 143 weeks)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) as Per Blinded Independent Central Review
percentage of participantsAdagrasibDocetaxel
Objective Response Rate (ORR) as Per Blinded Independent Central Review31.9 (26.7 to 37.5)9.2 (5.1 to 15.0)
Statistical analysis
  • Adagrasib vs Docetaxel · Cochran Mantel Haenszel chi-square test · p = <0.0001 · Odds ratio (or): 4.68 · 95% CI 2.56 to 8.56
SecondaryDuration of Response (DOR) as Per Blinded Independent Central Review

Duration of Response (DOR) in months is defined as the time from date of the first documentation of objective response (CR or PR) to the first documentation of PD or to death due to any cause in the absence of documented PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \< 10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. All target lesions must be assessed. Disease progression was defined as 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm.

Time frame:
First documentation of objective response (CR or PR) to the first documentation of PD or to death due to any cause (Up to approximately 22 months)
Reported as:
Median · months
Duration of Response (DOR) as Per Blinded Independent Central Review
monthsAdagrasibDocetaxel
Duration of Response (DOR) as Per Blinded Independent Central Review8.31 (6.05 to 10.35)5.36 (2.86 to 8.54)
Secondary1-Year Survival Rate
Time frame:
Up to 49 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

Treatment Emergent Adverse Events (TEAEs) are those that first occur or increase in severity on or after the first dose and not more than 28 days after the last dose, and prior to the initiation of subsequent systemic anti-cancer therapy. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsAdagrasibDocetaxelCrossover Adagrasib
Any TEAE29813844
Any Treatment-Related TEAE28012141
Any Treatment-Emergent SAE1495020
Any Treatment-Related Treatment-Emergent SAE62237
Any TEAE Leading to Discontinuation of Treatment40252
SecondaryNumber of Participants With Maximum CTCAE Grade Laboratory Abnormality in Hematology Parameters

Blood samples were collected to assess hematology parameters. Adverse events are graded on a scale from 0 to 4 based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0, with Grade 0 being normal Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.

Time frame:
From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Maximum CTCAE Grade Laboratory Abnormality in Hematology Parameters
ParticipantsAdagrasibDocetaxelCrossover Adagrasib
Anemia Grade 050165
Anemia Grade 11557426
Anemia Grade 274347
Anemia Grade 31683
Anemia Grade 4000
Anemia Missing383
Lymphocytes count decreased Grade 061339
Lymphocytes count decreased Grade 166207
Lymphocytes count decreased Grade 2713310
Lymphocytes count decreased Grade 352239
Lymphocytes count decreased Grade 4830
Lymphocytes count decreased Missing40289
Neutrophils count decreased Grade 02276132
Neutrophils count decreased Grade 110130
Neutrophils count decreased Grade 2870
Neutrophils count decreased Grade 34101
Neutrophils count decreased Grade 48212
Neutrophils count decreased Missing41289
Platelets count decreased Grade 020811335
Platelets count decreased Grade 174136
Platelets count decreased Grade 2830
Platelets count decreased Grade 3100
Platelets count decreased Grade 4300
Platelets count decreased Missing4113
White blood cell decreased Grade 02357236
White blood cell decreased Grade 136143
White blood cell decreased Grade 216151
White blood cell decreased Grade 37240
White blood cell decreased Grade 4041
White blood cell decreased Missing4113
SecondaryNumber of Participants With Maximum CTCAE Grade Laboratory Abnormality in Chemistry Parameters

Blood samples were collected to assess chemistry parameters. Adverse events are graded on a scale from 0 to 4 based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0, with Grade 0 being normal Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.

Time frame:
From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Maximum CTCAE Grade Laboratory Abnormality in Chemistry Parameters
ParticipantsAdagrasibDocetaxelCrossover Adagrasib
Alanine Aminotransferase increased Grade 011811823
Alanine Aminotransferase increased Grade 11071211
Alanine Aminotransferase increased Grade 22304
Alanine Aminotransferase increased Grade 33401
Alanine Aminotransferase increased Grade 4500
Alanine Aminotransferase increased Missing11105
Hypoalbuminemia Grade 01185519
Hypoalbuminemia Grade 11095113
Hypoalbuminemia Grade 258227
Hypoalbuminemia Grade 3100
Hypoalbuminemia Grade 4000
Hypoalbuminemia Missing12125
Hypercalcemia Grade 026010835
Hypercalcemia Grade 124193
Hypercalcemia Grade 2100
Hypercalcemia Grade 3000
Hypercalcemia Grade 4100
Hypercalcemia Missing12136
Hypocalcemia Grade 023011125
Hypocalcemia Grade 1451411
Hypocalcemia Grade 21122
Hypocalcemia Grade 3000
Hypocalcemia Grade 4000
Hypocalcemia Missing12136
Alkaline Phosphatase increased Grade 016510924
Alkaline Phosphatase increased Grade 1821914
Alkaline Phosphatase increased Grade 23121
Alkaline Phosphatase increased Grade 3800
Alkaline Phosphatase increased Grade 4100
Alkaline Phosphatase increased Missing11105
Amylase increased Grade 018110731
Amylase increased Grade 165117
Amylase increased Grade 21631
Amylase increased Grade 3600
Amylase increased Grade 4000
Amylase increased Missing30195
Aspartate Aminotransferase increased Grade 010311525
Aspartate Aminotransferase increased Grade 11331413
Aspartate Aminotransferase increased Grade 22701
Aspartate Aminotransferase increased Grade 32000
Aspartate Aminotransferase increased Grade 4300
Aspartate Aminotransferase increased Missing12115
Bilirubin increased Grade 025112537
Bilirubin increased Grade 12421
Bilirubin increased Grade 2911
Bilirubin increased Grade 3100
Bilirubin increased Grade 4200
Bilirubin increased Missing11125
Creatinine increased Grade 0999914
Creatinine increased Grade 155179
Creatinine increased Grade 21261115
Creatinine increased Grade 3631
Creatinine increased Grade 4100
Creatinine increased Missing11105
Fasted Hypoglycemia Grade 01466418
Fasted Hypoglycemia Grade 11542
Fasted Hypoglycemia Grade 2101
Fasted Hypoglycemia Grade 3000
Fasted Hypoglycemia Grade 4200
Fasted Hypoglycemia Missing1347223
Lipase Increased Grade 017710928
Lipase Increased Grade 16397
Lipase Increased Grade 22762
Lipase Increased Grade 31301
Lipase Increased Grade 4000
Lipase Increased Missing18166
Hypermagnesemia Grade 026512237
Hypermagnesemia Grade 11942
Hypermagnesemia Grade 2000
Hypermagnesemia Grade 3110
Hypermagnesemia Grade 4000
Hypermagnesemia Missing13135
Hypomagnesemia Grade 02139929
Hypomagnesemia Grade 1672510
Hypomagnesemia Grade 2530
Hypomagnesemia Grade 3000
Hypomagnesemia Grade 4000
Hypomagnesemia Missing13135
Non-Fasted Hypoglycemia Grade 01636622
Non-Fasted Hypoglycemia Grade 1983
Non-Fasted Hypoglycemia Grade 2100
Non-Fasted Hypoglycemia Grade 3000
Non-Fasted Hypoglycemia Grade 4300
Non-Fasted Hypoglycemia Missing1226619
Hyperkalemia Grade 020610728
Hyperkalemia Grade 154158
Hyperkalemia Grade 22063
Hyperkalemia Grade 3500
Hyperkalemia Grade 4110
Hyperkalemia Missing12115
Hypokalemia Grade 023711436
Hypokalemia Grade 143112
Hypokalemia Grade 2000
Hypokalemia Grade 3630
Hypokalemia Grade 4011
Hypokalemia Missing12115
Hypernatremia Grade 027213039
Hypernatremia Grade 11400
Hypernatremia Grade 2000
Hypernatremia Grade 3100
Hypernatremia Grade 4000
Hypernatremia Missing11105
Hyponatremia Grade 01359518
Hyponatremia Grade 11263219
Hyponatremia Grade 21731
Hyponatremia Grade 3700
Hyponatremia Grade 4201
Hyponatremia Missing11105
Hyperuricemia Grade 018510322
Hyperuricemia Grade 1982217
Hyperuricemia Grade 2000
Hyperuricemia Grade 3000
Hyperuricemia Grade 4000
Hyperuricemia Missing15155
SecondaryPlasma Concentration of Adagrasib

Blood samples were collected for assessment of plasma concentration of Adagrasib. Data for participants for which the dose was reduced after receiving starting dose of 600 mg BID, based on physician decision is presented in separate arms.

Time frame:
Day 1 of Cycle 1 (Pre-Dose and Peak), Cycle 2 (Pre-Dose and Peak), Cycle 3 (Pre-Dose), Cycle 5 (Pre-Dose), Cycle 7 (Pre-Dose) (Each cycle is of 21 days)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Plasma Concentration of Adagrasib
nanogram per milliliter (ng/mL)Adagrasib 200 mg BIDAdagrasib 400 mg QDAdagrasib 400 mg BIDAdagrasib 600 mg QDAdagrasib 600 mg BID
Cycle 1 Day 1 Pre-DoseNA ± NA—NA ± NANA ± NANA ± NA
Cycle 1 Day 1 PeakNA ± NA—NA ± NA556.963 ± 63.550518.944 ± 86.625
Cycle 2 Day 1 Pre-DoseNA ± NA—1579.040 ± 54.432NA ± NA2097.813 ± 67.912
Cycle 2 Day 1 Peak—NA ± NA2011.347 ± 39.3332331.298 ± 59.5152117.333 ± 62.744
Cycle 3 Day 1 Pre-Dose——NA ± NANA ± NA1865.408 ± 42.930
Cycle 5 Day 1 Pre-Dose——1114.046 ± 39.300917.541 ± 73.5961459.470 ± 39.094
Cycle 7 Day 1 Pre-Dose—NA ± NA1062.114 ± 33.842863.539 ± 42.9171548.018 ± 41.166
SecondaryChange From Baseline in Lung Cancer Symptom Scale (LCSS) Average Total Score

The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire assesses the following 6 symptoms items (appetite loss, fatigue, cough, dyspnea, hemoptysis, pain) and 3 summary global items (symptom distress, activity level, overall quality of life) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The LCSS average total score is sum of items 1 to 9 divided by the total number of items ((sum of items 1 to 9)/9) ranging from 0 to 100 where high score represent worst outcome. Least Square Mean and Confidence Interval are from a repeated measures model on the response variable change from baseline in LCSS average total score.

Time frame:
Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)
Reported as:
Least squares mean · Score on a sclae
Change From Baseline in Lung Cancer Symptom Scale (LCSS) Average Total Score
Score on a sclaeAdagrasibDocetaxel
Change From Baseline in Lung Cancer Symptom Scale (LCSS) Average Total Score-4.0 (-7.9 to -0.2)3.9 (-0.2 to 8.0)
SecondaryChange From Baseline in Lung Cancer Symptom Scale (LCSS) Average Symptom Burden Index Score

The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire for average symptom burden index score assesses the following six items (Appetite loss, fatigue, cough, shortness of breath, blood in sputum, pain) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The average symptom burden score is average of all the 6 items ranging from 0 to 100 where high score represent worst outcome. Least square mean and CI are from a repeated measures model on the response variable change from baseline in average symptom burden index score.

Time frame:
Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)
Reported as:
Least squares mean · Score on a sclae
Change From Baseline in Lung Cancer Symptom Scale (LCSS) Average Symptom Burden Index Score
Score on a sclaeAdagrasibDocetaxel
Change From Baseline in Lung Cancer Symptom Scale (LCSS) Average Symptom Burden Index Score-5.8 (-9.0 to -2.5)3.2 (-0.4 to 6.7)
SecondaryChange From Baseline in Lung Cancer Symptom Scale (LCSS) 3-Item Global Index Score

The Lung Cancer Symptom Scale (LCSS) is a disease measure of quality of life which evaluates six major lung cancer symptoms and their effect on overall distress and symptom severity, impact on day-to-day activities, and overall quality of life. This patient reported outcome (PRO) questionnaire for average 3-item global index score assesses the following 3 items (Distress/severity of symptoms from lung cancer, impact on normal activities, quality of life) for patients using visual analogue scales (VAS) (100 mm horizontal line) ranging from 0 (best rating) to 100 (worst rating). The 3 item global index score is average of all the 3 items ranging from 0 to 100 where high score represent worst outcome. LS mean and CI are from a repeated measures model on the response variable change from baseline in 3-item global index score.

Time frame:
Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)
Reported as:
Least squares mean · Score on a sclae
Change From Baseline in Lung Cancer Symptom Scale (LCSS) 3-Item Global Index Score
Score on a sclaeAdagrasibDocetaxel
Change From Baseline in Lung Cancer Symptom Scale (LCSS) 3-Item Global Index Score-3.0 (-20.3 to 14.3)15.9 (-2.6 to 34.3)
SecondaryChange From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Visual Analogue Scale Score

The Visual Analogue Score (VAS) is a component of the EQ-5D-5L and assesses the patient's self-rated health using a vertical visual analogue scale where numbered 0 (the worst health you can image) to 100 (the best health you can imageine). The smallest change considered clinically meaningful, is defined as a score difference of 7 points.

Time frame:
Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)
Reported as:
Least squares mean · Score on a scale
Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Visual Analogue Scale Score
Score on a scaleAdagrasibDocetaxel
Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Visual Analogue Scale Score0.1 (-4.4 to 4.5)-3.7 (-8.5 to 1.1)
SecondaryChange From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Health Utility Index Score

The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. The EQ-5D-5L health utility index (HUI) is assessed using the Crosswalk algorithm for France based on the individual responses to the 5 EQ-5D-5L domains ranging from -0.594 to 1.000. The smallest change considered clinically meaningful, is defined as a score difference of 0.08 points. Least square mean and CI are from a repeated measures model on the response variable change from baseline in health utility index.

Time frame:
Baseline (Day 1) and up to End of Treatment (Up to approximately 106 weeks)
Reported as:
Least squares mean · Score on a scale
Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Health Utility Index Score
Score on a scaleAdagrasibDocetaxel
Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Health Utility Index Score-0.0350 (-0.0977 to 0.0277)-0.0914 (-0.1572 to -0.0256)

Adverse events

Collected over All cause mortality and non serious adverse events were reported from first first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks). Serious adverse events were collected from date of signing of informed consent form till 28 days after last dose (Up to approximately 111 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adagrasib126/301 (41.9%)149/298 (50%)292/298 (98%)
Docetaxel53/152 (34.9%)50/140 (35.7%)129/140 (92.1%)
Crossover Adagrasib15/44 (34.1%)20/44 (45.5%)43/44 (97.7%)
Most frequent serious events
Showing 10 of 171
Most frequent serious events
EventAdagrasibDocetaxelCrossover Adagrasib
PneumoniaInfections and infestations11/2987/1406/44
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)22/2985/1405/44
DiarrhoeaGastrointestinal disorders4/2983/1402/44
VomitingGastrointestinal disorders9/2982/1401/44
Febrile neutropeniaBlood and lymphatic system disorders0/2984/1400/44
PyrexiaGeneral disorders7/2981/1400/44
MyelosuppressionBlood and lymphatic system disorders0/2982/1401/44
Cardiac failureCardiac disorders1/2980/1401/44
Cardio-respiratory arrestCardiac disorders0/2982/1401/44
Pericardial effusionCardiac disorders0/2981/1401/44
Most frequent other events
Showing 10 of 61
Most frequent other events
EventAdagrasibDocetaxelCrossover Adagrasib
DiarrhoeaGastrointestinal disorders169/29842/14029/44
VomitingGastrointestinal disorders121/29812/14016/44
NauseaGastrointestinal disorders114/29831/14015/44
AnaemiaBlood and lymphatic system disorders91/29848/14011/44
Alanine aminotransferase increasedInvestigations99/2984/1404/44
Aspartate aminotransferase increasedInvestigations99/2982/1405/44
AstheniaGeneral disorders81/29846/1409/44
Blood creatinine increasedInvestigations82/2984/14014/44
Decreased appetiteMetabolism and nutrition disorders94/29834/14012/44
AlopeciaSkin and subcutaneous tissue disorders3/29835/1400/44

Baseline characteristics

Age, Continuous
Age, Continuous(years)AdagrasibDocetaxelTotal
Mean63.6 ± 8.6663.9 ± 7.8163.7 ± 8.38
Sex: Female, Male
Sex: Female, Male(Participants)AdagrasibDocetaxelTotal
Female10842150
Male193110303
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AdagrasibDocetaxelTotal
Hispanic or Latino8614
Not Hispanic or Latino199111310
Unknown or Not Reported9435129
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AdagrasibDocetaxelTotal
White13581216
Black or African American000
Asian7237109
American Indian or Alaska Native000
Native Hawaiian or other Pacific Islander000
Other213
Not Reported8130111
Missing11314
08

Study locations

380 sites
  • Local Institution - 012-898
    Cerritos, California 90703, United States
  • Local Institution - 012-910
    Duarte, California 91010, United States
  • Local Institution - 012-898 D
    Glendale, California 91204, United States
  • Local Institution - 012-910-A
    Huntington Beach, California 92648, United States
  • Local Institution - 012-910-C
    Irvine, California 92618, United States
  • Local Institution - 012-910-B
    Long Beach, California 90808, United States
  • Local Institution - 012-910-F
    Long Beach, California 90813, United States
  • Local Institution - 012-910-D
    Newport Beach, California 92663, United States
  • Local Institution - 012-898 C
    Santa Ana, California 92705, United States
  • Local Institution - 012-858
    Santa Rosa, California 95403, United States
  • Local Institution - 012-910-E
    Torrance, California 90505, United States
  • Local Institution - 012-951-B
    Denver, Colorado 80218, United States
  • Local Institution - 012-951
    Lafayette, Colorado 80026, United States
  • Local Institution - 012-872
    Lone Tree, Colorado 80124, United States
  • Local Institution - 012-951-A
    Wheat Ridge, Colorado 80033-6005, United States
  • Local Institution - 012-562-B
    Fleming Island, Florida 32003, United States
  • Local Institution - 012-968
    Fort Lauderdale, Florida 33308, United States
  • Local Institution - 012-562-D
    Jacksonville, Florida 32204, United States
  • Local Institution - 012-853
    Jacksonville, Florida 32204, United States
  • Local Institution - 012-562-E
    Jacksonville, Florida 32207, United States
  • Local Institution - 012-562-A
    Jacksonville, Florida 32256, United States
  • Local Institution - 012-562-C
    Jacksonville, Florida 32256, United States
  • Local Institution - 012-562-F
    Jacksonville, Florida 32256, United States
  • Local Institution - 012-562-G
    Jacksonville, Florida 32256, United States
  • Local Institution - 012-562
    Jacksonville, Florida 32256, United States
  • Local Institution - 012-825
    Miami Beach, Florida 33140, United States
  • Local Institution - 012-973
    Orlando, Florida 32806, United States
  • Local Institution - 012-877
    Pensacola, Florida 32503, United States
  • Local Institution - 012-839
    Plantation, Florida 33322, United States
  • Local Institution - 012-941
    Athens, Georgia 30607, United States
  • Local Institution - 012-835 - A
    Austell, Georgia 30106, United States
  • Local Institution - 012-835 - B
    Carrollton, Georgia 30117, United States
  • Local Institution - 012-835 - C
    Cartersville, Georgia 30121, United States
  • Local Institution - 012-835 - D
    Douglasville, Georgia 30134, United States
  • Local Institution - 012-835
    Marietta, Georgia 30060, United States
  • Local Institution - 012-917
    Chicago, Illinois 60612, United States
  • Local Institution - 012-972
    Chicago, Illinois 60637, United States
  • Local Institution - 012-972 C
    Harvey, Illinois 60426, United States
  • Local Institution - 012-972 A
    New Lenox, Illinois 60451, United States
  • Local Institution - 012-883
    Niles, Illinois 60714, United States
  • Local Institution - 012-972 B
    Orland Park, Illinois 60462, United States
  • Local Institution - 012-943
    Goshen, Indiana 46526, United States
  • Local Institution - 012-569
    Indianapolis, Indiana 46237, United States
  • Local Institution - 012-569 - B
    Lafayette, Indiana 47905, United States
  • Local Institution - 012-569 - C
    Lafayette, Indiana 47905, United States
  • Local Institution - 012-569 - A
    Mooresville, Indiana 46158, United States
  • Local Institution - 012-782
    Munster, Indiana 46321, United States
  • Local Institution - 012-942-B
    Chanute, Kansas 66720, United States
  • Local Institution - 012-942-C
    Dodge City, Kansas 67801, United States
  • Local Institution - 012-942-D
    El Dorado, Kansas 67042, United States
  • Local Institution - 012-942-E
    Independence, Kansas 67301, United States
  • Local Institution - 012-942-F
    Kingman, Kansas 67068, United States
  • Local Institution - 012-942-G
    Liberal, Kansas 67901, United States
  • Local Institution - 012-942-H
    McPherson, Kansas 67460, United States
  • Local Institution - 012-942-I
    Newton, Kansas 67114, United States
  • Local Institution - 012-942-J
    Parsons, Kansas 67357, United States
  • Local Institution - 012-942-K
    Pratt, Kansas 67124, United States
  • Local Institution - 012-942-L
    Salina, Kansas 67401, United States
  • Local Institution - 012-942-M
    Wellington, Kansas 67152, United States
  • Local Institution - 012-820
    Westwood, Kansas 66205, United States
  • Local Institution - 012-942-A
    Wichita, Kansas 67208, United States
  • Local Institution - 012-942
    Wichita, Kansas 67214, United States
  • Local Institution - 012-942-N
    Winfield, Kansas 67156, United States
  • Local Institution - 012-965
    Lexington, Kentucky 40503, United States
  • Local Institution - 012-911 A
    New Orleans, Louisiana 70112, United States
  • Local Institution - 012-911
    New Orleans, Louisiana 70112, United States
  • Local Institution - 012-954 - A
    Kennebunk, Maine 04043, United States
  • Local Institution - 012-954
    Scarborough, Maine 04074, United States
  • Local Institution - 012-954 - B
    Topsham, Maine 04086, United States
  • Local Institution - 012-856
    Frederick, Maryland 21702, United States
  • Local Institution - 012-974-B
    Novi, Michigan 48374, United States
  • Local Institution - 012-974-C
    Novi, Michigan 48374, United States
  • Local Institution - 012-974-A
    Southfield, Michigan 48075, United States
  • Local Institution - 012-974
    Southfield, Michigan 48075, United States
  • Local Institution - 012-952
    Bolivar, Missouri 65613, United States
  • Local Institution - 012-841 - A
    Billings, Montana 59101, United States
  • Local Institution - 012-841
    Billings, Montana 59101, United States
  • Local Institution - 012-846
    Billings, Montana 59102, United States
  • Local Institution - 012-975
    East Brunswick, New Jersey 08816, United States
  • Local Institution - 012-975 - A
    Edison, New Jersey 08820, United States
  • Local Institution - 012-975 - B
    Monroe, New Jersey 08831, United States
  • Local Institution - 012-975 - C
    Somerset, New Jersey 08873, United States
  • Local Institution - 012-975 - D
    Somerville, New Jersey 08876, United States
  • Local Institution - 012-577
    Teaneck, New Jersey 07666, United States
  • Local Institution - 012-962
    Syracuse, New York 13210-2306, United States
  • Local Institution - 012-849
    Cleveland, Ohio 44106, United States
  • Local Institution - 012-836
    Kettering, Ohio 45429, United States
  • Local Institution - 012-967
    Salem, Oregon 97301, United States
  • Local Institution - 012-960
    Providence, Rhode Island 02903, United States
  • Local Institution - 012-960-A
    Providence, Rhode Island 02906, United States
  • Local Institution - 012-891
    Greenville, South Carolina 29605, United States
  • Local Institution - 012-940
    Sioux Falls, South Dakota 57105, United States
  • Local Institution - 012-888
    Arlington, Texas 76012, United States
  • Local Institution - 012-892
    Austin, Texas 78745, United States
  • Local Institution - 012-999
    Irving, Texas 75063, United States
  • Local Institution - 012-890
    Sherman, Texas 75090, United States
  • Local Institution - 012-976
    Salt Lake City, Utah 84106, United States
  • Local Institution - 012-976-A
    Salt Lake City, Utah 84124, United States
  • Local Institution - 012-976-B
    Salt Lake City, Utah 84124, United States
  • Local Institution - 012-976-C
    Salt Lake City, Utah 84124, United States

Showing the first 100 of 380 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Barlesi F, Yao W, Duruisseaux M, Doucet L, Martinez AA, Gregorc V, Juan-Vidal O, Lu S, De Bondt C, de Marinis F, Linardou H, Kim YC, Jotte R, Felip E, Lo Russo G, Reck M, Michenzie MF, Yang W, Meade JN, Korytowsky B, Mok TSK; KRYSTAL-12 Investigators. Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. Lancet. 2025 Aug 9;406(10503):615-626. doi: 10.1016/S0140-6736(25)00866-9. PubMed 40783289 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Dec 2023, 34 months.

Results were first posted in Jan 2025, 1 year after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 34 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2020
First posted
Dec 28, 2020
StartActual
Feb 23, 2021
Primary completionActual
Dec 30, 2023
CompletionEst.
Oct 30, 2026
Results first posted
Jan 22, 2025
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04685135
Responsible party
Sponsor
First posted
Dec 28, 2020
Start date
Feb 23, 2021
Primary completion
Dec 30, 2023
Completion
Oct 30, 2026 (estimated)
Results posted
Jan 22, 2025
Last update
Aug 11, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adagrasib

Start the discussion